Assessment of minimal residual disease (MRD) is rapidly transforming the prognostic and therapeutic landscape of a wide gamut of haematological malignancies (Beldjord et al, 2014; Ribera et al, 2014; Mailankody et al, 2015; Roschewski et al, 2015; Cheminant et al, 2016; Flores-Montero et al, 2017; Scherer et al, 2017 ). An evolving body of literature indicates that acute myeloid leukaemia (AML) is no exception to this emerging theme; indeed, it is becoming well established that the presence of MRD is significant in several key clinical settings in this disease. Previously published data from the Dutch-Belgian Haemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research cooperative group (Terwijn et al, 2013) , the UK National Cancer Research Institute (Freeman et al, 2013) , the Seattle group Othus et al, 2016) and others have established MRD status following initial induction treatment as a powerful independent prognosticator of patient outcome in AML. In the same vein, the importance of pre-transplantation MRD status is gaining appreciation based on several notable publications showing significantly inferior outcomes for AML patients with positive MRD studies prior to transplantation (Anthias et al, 2014; Walter et al, 2015; Ustun et al, 2016; Buckley et al, 2017; Oran et al, 2017) , and also possibly the clinical benefit accrued by an allogeneic stem cell transplantation in AML patients with a suboptimal MRD response to initial induction chemotherapy (Balsat et al, 2017) . With the increased use of haploidentical stem cell transplantation (haplo-SCT) in acute leukaemia patients (Bashey et al, 2013 (Bashey et al, , 2017 Luo et al, 2014; Ciurea et al, 2015; Piemontese et al, 2015 Piemontese et al, , 2017 Han et al, 2017; Lee et al, 2017) , it is becoming increasingly imperative to determine the role pre-transplant MRD studies may assume in prognostication of patients with AML undergoing haplo-SCT. Yet there is currently a paucity of data regarding the implications of a positive MRD state prior to haploidentical stem cell transplantation. The aims of this study were to assess the potential impact of pre-transplant MRD on AML patients undergoing haplo-SCT, and to characterize in detail prognostic factors affecting the specific outcome of MRD-positive and MRD-negative patients.
Methods

Study cohort
This retrospective analysis was comprised of patients enrolled on the multicentre registry of the Acute Leukaemia Working Party (ALWP), which forms part of the European Society of Blood and Marrow Transplantation (EBMT). Adults over the age of 18 years with de novo AML were included in this analysis if they underwent a first T-cell replete haplo-SCT at first or second remission, and their molecular status (i.e. MRD) was available at the time of transplant. All patients provided written informed consent authorising the use of their personal information for research purposes. This study was approved by the ALWP institutional review board and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Disease risk and response classification
Cytogenetic risk was assessed according to the European LeukaemiaNet criteria (Dohner et al, 2010) . The clinical endpoints assessed in this analysis were leukaemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD), GVHDfree/relapse-free survival (GRFS), defined as events including grade 3-4 acute GVHD, severe chronic GVHD, relapse or death in the first year post-SCT (GRFS) (Ruggeri et al, 2016) , and overall survival (OS). LFS was defined as survival with no evidence of relapse or progression. Relapse was defined as the reappearance of >5% bone marrow blasts and/or an extramedullary disease site resulting from blast cell infiltration. NRM was defined as death without evidence of relapse or progression. OS was defined as the time from haplo-SCT to death, regardless of the cause. Acute and chronic GVHD were classified and graded according to established criteria (Przepiorka et al, 1995; Filipovich et al, 2005) . Intensity of conditioning was determined according to previously published EBMT criteria (Aoudjhane et al, 2005) . Assessment of MRD was performed locally and reported by participating centres.
Statistical analysis
Cumulative incidence was used to estimate the endpoints of NRM, RI, acute GVHD and chronic GVHD to accommodate for competing risks. To study acute and chronic GVHD, we considered relapse and death to be competing events. Probabilities of OS, LFS and GRFS were calculated using the Kaplan-Meier method. Univariate analyses were done using Gray's test for cumulative incidence functions and the log rank test for OS, GRFS and LFS. A Cox proportional hazards model was used for multivariate regression. All variables differing significantly between the 2 groups (i.e. MRD pos and MRD neg patients) or factors associated with one outcome in univariate analysis were included in the Cox model. As planned in the protocol, multivariate analyses were also performed separately according to the MRD status at transplant. In order to test for a centre effect, we introduced a random effect or frailty for each centre into the model (Hougaard, 1995; Andersen et al, 1999) . Results were expressed as the hazard ratio (HR) with 95% confidence interval (95% CI). All factors were tested for the proportional hazards assumption using the Grambsch-Therneau residual-based test. As we found a departure from the proportionality assumption for the impact of MRD status with time, we used a step function for estimating the variation of the coefficient associated with this variable with time. i.e., different coefficients over different time intervals post-transplant (0-3 months, 3-6 months and more than 6 months) (Therneau et al, 2016) . We found that the effect of MRD was significantly associated with the outcome after 6 months. We then ran a landmark analysis using a starting point of 6 months following transplant. All tests were two-sided with the type I error rate fixed at 0Á05 for the determination of factors associated with time to-event outcomes. Statistical analyses were performed with SPSS 24.0 (SPSS Inc, Chicago, IL, USA) and R 3.4.0 (R Core Team (2017).
Results
Patients
A cohort consisting of 393 AML patients who underwent haplo-SCT between 2006 and 2016 with available MRD data was identified and analysed. The median age of patients was comparable between patients with pre-transplant negative MRD studies and positive MRD studies, 47 and 48 years, respectively (Table I) . MRD neg patients were more likely to harbour high risk baseline cytogenetic studies (15% vs. 7%; P < 0Á001) whereas MRD pos patients were more often observed to have favourable risk baseline cytogenetic studies (23% vs. 9%; P < 0Á001). Of note, MRD neg patients were more likely to be NPM1 wt compared to their MRD pos counterparts (66% vs. 46%; P = 0Á01), however the rate of FLT3-internal tandem duplication (ITD) was not significantly different in both groups. There were no statistically significant differences between MRD neg and MRD pos patients in terms of cytomegalovirus (CMV) donor-recipient matching (P = 0Á12), use of anti-thymocyte globulin (ATG) Iposttransplant cyclophosphamide (PTCy) (P = 0Á7), engraftment rate (P = 0Á5) and conditioning intensity (P = 0Á7). The various conditioning regimens used are outlined in Table S1 . Relapse At the 2-year mark, the rate of relapse for the cohort as a whole was 22% (95% CI: 17Á6-27Á1). The risk of relapse was significantly higher in the MRD pos group wherein 37% of patients experienced relapse compared to 16% of patients with negative MRD studies (P = 0Á0003). In an adjusted Cox regression model (Table S2) , negative MRD status was independently associated with decreased incidence of relapse (HR = 0Á31, CI 95%, 0Á18-0Á56; P < 0Á0001). As shown in Table S3 , this effect was confirmed also in an additional multivariate analysis conducted on the subgroup of patients in first remission (CR1), i.e., MRD neg patients experienced a significantly reduced risk of relapse compared to MRD pos patients (HR = 0Á32, CI 95%, 0Á17-0Á61; P = 0Á0005).
Non-relapse mortality
The incidence of NRM at 2 years was 22% (95% CI: 17Á3-26Á6 MRD neg patients (P = 0Á16). As outlined in Table S4 , leukaemia, GVHD and infection accounted for most deaths in the analysed cohort.
Leukaemia-free survival and overall survival
The 2-year rate of LFS and OS in this patient cohort was 56% (95% CI: 50Á1-61Á6) and 63% (95% CI: 57Á2-68Á4), respectively. There was a trend towards inferior LFS survival in MRD pos patients which did not reach statistical significance (44% vs. 60%; P = 0Á088). Overall survival was not significantly impacted by MRD status (P = 0Á18). Subsequently, a multivariate regression analysis confirmed MRD status to be independently prognostic of LFS (HR = 0Á62, CI 95%, 0Á41-0Á93; P = 0Á023).
Graft-versus-host disease and graft-versus-host disease free/relapse-free survival
Grade II-IV acute GVHD was experienced by 29% (95% CI: 24-33Á1) of patients in the analysed cohort whereas chronic GVHD was diagnosed in 32% (95% CI: 26Á5-37Á3) at 2 years of follow-up. Neither acute GVHD nor chronic GVHD rates were significantly impacted by MRD positivity. Extensive chronic GVHD was seen in 9Á6% of patients and was comparable between MRD pos and MRD neg patients (P = 0Á8). The 2-year incidence of GRFS was 49% (95% CI: 43-54Á6) and was also not significantly impacted by MRD status (P = 0Á2).
Landmark analysis at 6 months from transplantation
As shown in Fig 1, the benefit of MRD negativity was evident at circa 6 months following transplant when the curves begin to separate for RI, LFS, GRFS and OS. Thus, we performed an additional analysis at the 6-month time point which, as shown in Table II and Fig 2, confirmed that at this interval MRD positivity was significantly and independently associated with inferior rates of relapse, LFS, GRFS and OS.
Subgroup analysis of patients according to MRD status
To further characterize the impact of MRD status on outcome following haplo-SCT, we subsequently performed separate analyses for MRD pos and MRD neg patients. In MRD pos patients, transplant at first or second remission, as well as mutations in FLT3-ITD and NPM1 were found to bear no significant impact on both disease-and transplant-related outcomes. In multivariate analysis, MRD pos patients with CMV + donors had significantly decreased relapse rates as well as better LFS, OS and GRFS rates (Table III) . In addition, MRD pos patients who underwent myeloablative conditioning and those treated with PTCy experienced a lower incidence of chronic GVHD. In MRD neg patients, multivariate analysis did not reveal any significant risk factor impacting on disease-or transplant-related outcomes. ATG, anti-thymocyte globulin; CI, 95% confidence interval; CR1/2, first/second complete remission; GRFS, graft versus host disease-free/relapse-free survival; HR, hazard ratio; LFS, leukaemia-free survival; MAC, myeloablative conditioning; MRD, minimal residual disease; NRM, non-relapse mortality; OS, overall survival; PTCy, post-transplant cyclophosphamide; RI, relapse incidence; RIC, reduced intensity conditioning. 
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Discussion
Incorporation of MRD platforms into the diagnostic and therapeutic management paradigm of patients with AML is proving to be a transformative approach in the risk stratification of patients with this clinically challenging disease. In this analysis we extend on the established MRD experience in related and unrelated donors (Freeman et al, 2013; Terwijn et al, 2013; Chen et al, 2015; Othus et al, 2016) and show that, in haplo-SCT pre-transplant, MRD status also holds a significant prognostic role. Our data indicate that patients with positive MRD studies prior to haplo-SCT experience significantly increased relapse rates compared to MRD neg patients. Moreover, we establish pre-transplant MRD status to be an independent predictor of LFS whereby MRD neg patients have clearly superior rates of achievement of LFS compared to their MRD pos counterparts. ATG, anti-thymocyte globulin; CI, 95% confidence interval; CMV, cytomegalovirus; CR1/2, first/second complete remission; GRFS, GVHD-free/relapse-free survival; GVHD, graft versus host disease; HR, hazard ratio; LFS, leukaemia-free survival; MAC, myeloablative conditioning; MRD, minimal residual disease; NRM, non-relapse mortality; OS, overall survival; PTCy, post-transplant cyclophosphamide; RI, relapse incidence; RIC, reduced intensity conditioning. (Oran et al, 2017) . Furthermore, the predictive value of MRD extends into patients conditioned both with myeloablative as well as reduced intensity conditioning, as shown by reports from the UK (Anthias et al, 2014) and the US , although we note some data suggesting that myeloablative conditioning may be superior in the setting of pre-transplant MRD-positive disease (Ustun et al, 2016) . Furthermore, a recently published meta-analysis of 19 studies lays further credence to the concept of pre-transplant MRD by showing pre-transplant MRD status to be independently associated with inferior LFS and disease relapse, irrespective of detection method (Buckley et al, 2017) . Finally, pre-transplant MRD status may be pivotal in determination of post-induction therapy intensity, as suggested by the results of the ALFA-0702 trial, in NPM1 mutated AML patients, which showed that the clinical benefit of allogeneic transplantation was only seen in patients who had detectable peripheral blood MRD levels following initial induction therapy as opposed to those who had undetectable MRD levels (Balsat et al, 2017) . Interestingly, in MRD pos patients, harbouring either a FLT3-ITD or NPM1 mutation did not affect relapse or LFS rates. These findings concur with the MD Anderson experience who also found that in patients with pre-transplant MRD-positive studies, RI was not significantly different between FLT3-ITD mutated patients and FLT3 wt patients (Oran et al, 2017) . Similar findings were published by Chen et al (2015) who observed that consideration of MRD status rendered FLT3-ITD and NPM1 mutational status as much weaker determinants of relapse. Thus, the marked deleterious prognostic influence imparted by a positive pre-transplant MRD study seems to outweigh the prognostic effect of either FLT3-ITD or NPM1.
As haplo-SCT gains in acceptance, it is becoming increasingly important to determine whether pre-transplant MRD assessment is clinically impactful also with this transplant modality. Our analysis reaffirms the significant impact of pretransplant MRD on relapse and LFS. Moreover, the six-month landmark analysis reveals that the full magnitude of clinical benefit of an MRD-negative state, in terms of OS, is realized at this time point. Interestingly, these results contrast with those of a previously published analysis looking at the outcomes of 240 AML patients undergoing haplo-SCT and which did not find pre-transplant positive MRD studies to be associated with inferior clinical outcomes (Chang et al, 2017) . The divergence in results may be possibly accounted by the different patient milieu analysed in both cohorts where ours consisted of significantly older patients (median age of 47 years compared to 27 years), different disease characteristics (our analysis included only patients with de novo AML), conditioning intensity [Chang et al (2017) used solely myeloablative conditioning], and differences in GVHD prophylaxis (i.e. ATG, PTCy). As stated earlier, a survival advantage for MRD neg patients was seen only at the 6-month mark, a fact that could be possibly accounted for by a smaller effect in haplo-transplants compared to what was seen in similar analyses in matched donor transplants. Alternatively, our sample size or heterogeneity of platforms used for MRD detection could be additional possible reasons. A definitive answer to this question would be optimally addressed by future prospective studies in this patient population. This analysis was limited by the retrospective nature of this study, which did not allow for specific assessment of the various MRD platforms used by the participating centres, as well as their specific sensitivity thresholds. As our cohort was comprised solely of transplanted patients we acknowledge the inherent selection bias which needs to be taken into consideration when interpreting of our findings. Future studies focusing on specific MRD modalities will help in further delineating the prognostic role of MRD in haplo-SCT.
Collectively, our data further support the emerging role of pre-transplant MRD in risk stratification of AML patients and indicate that MRD status is potentially a pivotal determinant of outcome in AML patients undergoing haplo-SCT. It is hoped and anticipated that pre-emptive and maintenance therapy with existing therapies, such as hypomethylating agents (Sockel et al, 2011; Platzbecker et al, 2012) , FLT3 inhibitors (Battipaglia et al, 2017; Sandmaier et al, 2018) and immunotherapy (Di Grazia et al, 2016) , as well as the introduction of novel agents will reduce relapse rates and improve outcomes in this high risk patient population.
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